TY - JOUR
T1 - STI571
T2 - A paradigm of new agents for cancer therapeutics
AU - Mauro, Michael J.
AU - O'Dwyer, Michael
AU - Heinrich, Michael C.
AU - Druker, Brian J.
PY - 2002/1/1
Y1 - 2002/1/1
N2 - STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.
AB - STI571 exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose selection, optimizing therapy, and predicting response, as are possible mechanisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm to other malignancies are explored.
UR - http://www.scopus.com/inward/record.url?scp=0036139993&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036139993&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.1.325
DO - 10.1200/JCO.20.1.325
M3 - Article
C2 - 11773186
AN - SCOPUS:0036139993
SN - 0732-183X
VL - 20
SP - 325
EP - 334
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 1
ER -